Reporter brief
RCT of metformin combinations to maintain weight loss after GLP-1 medication cessation, results not yet reported
What happened
This is a randomized controlled trial protocol comparing four groups (control, metformin alone, metformin plus rapamycin, and metformin plus naltrexone) in patients discontinuing GLP-1 receptor agonists. The study aims to assess whether these interventions reduce weight regain over six months post-cessation and improve metabolic markers. No results have been reported; this appears to be a study design document rather than outcome data.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients weaning off GLP-1 medications who have achieved weight loss
- Design
- Rct
- Sample
- —
- Journal
- AgelessRx
- Published
- Jul 30, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.